Measures of Oxidative Stress

Clinics in Laboratory Medicine

Volumn 26, Issue 3, 2006, Pages 571-590

  Tsimikas, Sotirios ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ATORVASTATIN; BIOLOGICAL MARKER; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; ISOPROSTANE DERIVATIVE; MONOCLONAL ANTIBODY; OXIDIZED LOW DENSITY LIPOPROTEIN;

ACCURACY; ATHEROSCLEROSIS; CARDIOVASCULAR RISK; CORONARY ARTERY DISEASE; DRUG MECHANISM; EPIDEMIOLOGICAL DATA; HUMAN; LABORATORY TEST; LIPID ANALYSIS; LIPOPROTEIN BLOOD LEVEL; OXIDATIVE STRESS; PATHOPHYSIOLOGY; PREDICTION; PRIORITY JOURNAL; RELIABILITY; REVIEW; RISK ASSESSMENT; SENSITIVITY AND SPECIFICITY;

ANIMALS; BIOLOGICAL MARKERS; CARDIOVASCULAR DISEASES; HUMANS; ISOPROSTANES; LIPOPROTEINS, LDL; OXIDATIVE STRESS; RISK FACTORS;

EID: 33748153794     PISSN: 02722712     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cll.2006.06.004     Document Type: Review

References (96)

1. Manolio T. Novel risk markers and clinical practice. N Engl J Med 349 (2003) 1587-1589
2. Tsimikas S., Glass C., Steinberg D., et al. Lipoproteins, lipoprotein oxidation and atherogenesis. Molecular basis of cardiovascular disease. A companion to Braunwald's heart disease. In: Chien K.R. (Ed) (2004), W.B. Saunders Company, Philadelphia 385-413
3. Navab M., Ananthramaiah G.M., Reddy S.T., et al. Thematic review series: the pathogenesis of atherosclerosis: the oxidation hypothesis of atherogenesis: the role of oxidized phospholipids and HDL. J Lipid Res 45 (2004) 993-1007
4. Tsimikas S., and Witztum J.L. Measuring circulating oxidized low-density lipoprotein to evaluate coronary risk. Circulation 103 (2001) 1930-1932
5. Cyrus T., Witztum J.L., Rader D.J., et al. Disruption of the 12/15-lipoxygenase gene diminishes atherosclerosis in apo E-deficient mice. J Clin Invest 103 (1999) 1597-1604
6. Cai H. NAD(P)H oxidase-dependent self-propagation of hydrogen peroxide and vascular disease. Circ Res 96 (2005) 818-822
7. Hazen S.L. Myeloperoxidase and plaque vulnerability. Arterioscler Thromb Vasc Biol 24 (2004) 1143-1146
8. Tsimikas S. Oxidized low-density lipoprotein biomarkers in atherosclerosis. Curr Atheroscler Rep 8 (2006) 55-61
9. Tsimikas S., Shortal B.P., Witztum J.L., et al. In vivo uptake of radiolabeled MDA2, an oxidation-specific monoclonal antibody, provides an accurate measure of atherosclerotic lesions rich in oxidized LDL and is highly sensitive to their regression. Arterioscler Thromb Vasc Biol 20 (2000) 689-697
10. Palinski W., and Napoli C. The fetal origins of atherosclerosis: maternal hypercholesterolemia, and cholesterol-lowering or antioxidant treatment during pregnancy influence in utero programming and postnatal susceptibility to atherogenesis. FASEB J 16 (2002) 1348-1360
11. Crisby M., Nordin-Fredriksson G., Shah P.K., et al. Pravastatin treatment increases collagen content and decreases lipid content, inflammation, metalloproteinases, and cell death in human carotid plaques: implications for plaque stabilization. Circulation 103 (2001) 926-933
12. Torzewski M., Shaw P.X., Han K.R., et al. Reduced in vivo aortic uptake of radiolabeled oxidation-specific antibodies reflects changes in plaque composition consistent with plaque stabilization. Arterioscler Thromb Vasc Biol 24 (2004) 2307-2312
13. Aikawa M., Sugiyama S., Hill C.C., et al. Lipid lowering reduces oxidative stress and endothelial cell activation in rabbit atheroma. Circulation 106 (2002) 1390-1396
14. Libby P. Inflammation in atherosclerosis. Nature 420 (2002) 868-874
15. Holvoet P., Perez G., Zhao Z., et al. Malondialdehyde-modified low density lipoproteins in patients with atherosclerotic disease. J Clin Invest 95 (1995) 2611-2619
16. Itabe H., Yamamoto H., Imanaka T., et al. Sensitive detection of oxidatively modified low density lipoprotein using a monoclonal antibody. J Lipid Res 37 (1996) 45-53
17. Palinski W., Hörkkö S., Miller E., et al. Cloning of monoclonal autoantibodies to epitopes of oxidized lipoproteins from apolipoprotein E-deficient mice. Demonstration of epitopes of oxidized low density lipoprotein in human plasma. J Clin Invest 98 (1996) 800-814
18. Itabe H., Takeshima E., Iwasaki H., et al. A monoclonal antibody against oxidized lipoprotein recognizes foam cells in atherosclerotic lesions. Complex formation of oxidized phosphatidylcholines and polypeptides. J Biol Chem 269 (1994) 15274-15279
19. Hörkkö S., Bird D.A., Miller E., et al. Monoclonal autoantibodies specific for oxidized phospholipids or oxidized phospholipid-protein adducts inhibit macrophage uptake of oxidized low-density lipoproteins. J Clin Invest 103 (1999) 117-128
20. Holvoet P., Donck J., Landeloos M., et al. Correlation between oxidized low density lipoproteins and von Willebrand factor in chronic renal failure. Thromb Haemost 76 (1996) 663-669
21. Holvoet P., Van Cleemput J., Collen D., et al. Oxidized low density lipoprotein is a prognostic marker of transplant-associated coronary artery disease. Arterioscler Thromb Vasc Biol 20 (2000) 698-702
22. Calara F., Dimayuga P., Niemann A., et al. An animal model to study local oxidation of LDL and its biological effects in the arterial wall. Arterioscler Thromb Vasc Biol 18 (1998) 884-893
23. Van Berkel T.J., De Rijke Y.B., and Kruijt J.K. Different fate in vivo of oxidatively modified low density lipoprotein and acetylated low density lipoprotein in rats. Recognition by various scavenger receptors on Kupffer and endothelial liver cells. J Biol Chem 266 (1991) 2282-2289
24. Gillotte-Taylor K., Boullier A., Witztum J.L., et al. Scavenger receptor class B type I as a receptor for oxidized low density lipoprotein. J Lipid Res 42 (2001) 1474-1482
25. Friedman P., Hörkkö S., Steinberg D., et al. Correlation of antiphospholipid antibody recognition with the structure of synthetic oxidized phospholipids: importance of Schiff base formation and Aldol condensation. J Biol Chem 277 (2001) 7010-7020
26. Binder C.J., Horkko S., Dewan A., et al. Pneumococcal vaccination decreases atherosclerotic lesion formation: molecular mimicry between Streptococcus pneumoniae and oxidized LDL. Nat Med 9 (2003) 736-743
27. Shaw P.X., Hörkkö S., Chang M.K., et al. Natural antibodies with the T15 idiotype may act in atherosclerosis, apoptotic clearance, and protective immunity. J Clin Invest 105 (2000) 1731-1740
28. Young S.G., Smith R.S., Hogle D.M., et al. Two new monoclonal antibody-based enzyme-linked assays of apolipoprotein B. Clin Chem 32 (1986) 1484-1490
29. Tsimikas S., Bergmark C., Beyer R.W., et al. Temporal increases in plasma markers of oxidized low-density lipoprotein strongly reflect the presence of acute coronary syndromes. J Am Coll Cardiol 41 (2003) 360-370
30. Tsimikas S., Lau H.K., Han K.R., et al. Percutaneous coronary intervention results in acute increases in oxidized phospholipids and lipoprotein(a): short-term and long-term immunologic responses to oxidized low-density lipoprotein. Circulation 109 (2004) 3164-3170
31. Tsimikas S., Witztum J.L., Miller E.R., et al. High-dose atorvastatin reduces total plasma levels of oxidized phospholipids and immune complexes present on apolipoprotein B-100 in patients with acute coronary syndromes in the MIRACL trial. Circulation 110 (2004) 1406-1412
32. Tsimikas S., Kiechl S., Willeit J., et al. Oxidized phospholipids predict the presence and progression of carotid and femoral atherosclerosis and symptomatic cardiovascular disease: five-year prospective results from the Bruneck study. J Am Coll Cardiol 47 (2006) 2219-2228
33. Holvoet P., Harris T.B., Tracy R.P., et al. Association of high coronary heart disease risk status with circulating oxidized LDL in the well-functioning elderly: findings from the health, aging, and body composition study. Arterioscler Thromb Vasc Biol 23 (2003) 1444-1448
34. Sigurdardottir V., and Fagerberg B. Circulating oxidized low-density lipoprotein (LDL) is associated with risk factors of the metabolic syndrome and LDL size in clinically healthy 58-year-old men (AIR study). J Intern Med 252 (2002) 440-447
35. Hulthe J., and Fagerberg B. Circulating oxidized LDL is associated with subclinical atherosclerosis development and inflammatory cytokines (AIR Study). Arterioscler Thromb Vasc Biol 22 (2002) 1162-1167
36. Liu M.L., Ylitalo K., Salonen R., et al. Circulating oxidized low-density lipoprotein and its association with carotid intima-media thickness in asymptomatic members of familial combined hyperlipidemia families. Arterioscler Thromb Vasc Biol 24 (2004) 1492-1497
37. Suzuki T., Kohno H., and Toshima S. Diagnostic implications of circulating oxidized low density lipoprotein levels as a biochemical risk marker of atherosclerotic disease. Circulation 104 (2001) II-248A
38. Rodenburg J., Vissers M.N., Wiegman A., et al. Oxidized low-density lipoprotein in children with familial hypercholesterolemia and unaffected siblings: the effect of pravastatin. J Am Coll Cardiol 47 (2006) 1803-1810
39. Tsimikas S., Brilakis E.S., Miller E.R., et al. Oxidized phospholipids, Lp(a) lipoprotein, and coronary artery disease. N Engl J Med 353 (2005) 46-57
40. Bergmark C., Tsimikas S., and Witztum J.L. A possible novel function for lipoprotein(a) as a carrier of oxidized phospholipids. Arterioscler Thromb Vasc Biol 25 (2004) e71
41. Tamai O., Matsuoka H., Itabe H., et al. Single LDL apheresis improves endothelium-dependent vasodilatation in hypercholesterolemic humans. Circulation 95 (1997) 76-82
42. Kobayashi J., Katsube S., Shimoda M., et al. Single LDL apheresis improves serum remnant-like particle-cholesterol, C-reactive protein, and malondialdehyde-modified-low-density lipoprotein concentrations in Japanese hypercholesterolemic subjects. Clin Chim Acta 321 (2002) 107-112
43. Penny W.F., Ben Yehuda O., Kuroe K., et al. Improvement of coronary artery endothelial dysfunction with lipid-lowering therapy: heterogeneity of segmental response and correlation with plasma-oxidized low density lipoprotein. J Am Coll Cardiol 37 (2001) 766-774
44. Matsumoto T., Takashima H., Ohira N., et al. Plasma level of oxidized low-density lipoprotein is an independent determinant of coronary macrovasomotor and microvasomotor responses induced by bradykinin. J Am Coll Cardiol 44 (2004) 451-457
45. Kugiyama K., Sugiyama S., Soejima H., et al. Increase in plasma levels of oxidized low-density lipoproteins in patients with coronary spastic angina. Atherosclerosis 154 (2001) 463-467
46. Tanaga K., Bujo H., Inoue M., et al. Increased circulating malondialdehyde-modified LDL levels in patients with coronary artery diseases and their association with peak sizes of LDL particles. Arterioscler Thromb Vasc Biol 22 (2002) 662-666
47. Sjogren P., Basu S., Rosell M., et al. Measures of oxidized low-density lipoprotein and oxidative stress are not related and not elevated in otherwise healthy men with the metabolic syndrome. Arterioscler Thromb Vasc Biol 25 (2005) 2580-2586
48. Jarvisalo M.J., Lehtimaki T., and Raitakari O.T. Determinants of arterial nitrate-mediated dilatation in children: role of oxidized low-density lipoprotein, endothelial function, and carotid intima-media thickness. Circulation 109 (2004) 2885-2889
49. Silaste M.L., Rantala M., Alfthan G., et al. Changes in dietary fat intake alter plasma levels of oxidized low-density lipoprotein and lipoprotein(a). Arterioscler Thromb Vasc Biol 24 (2004) 498-503
50. Toshima S., Hasegawa A., Kurabayashi M., et al. Circulating oxidized low density lipoprotein levels: a biochemical risk marker for coronary heart disease. Arterioscler Thromb Vasc Biol 20 (2000) 2243-2247
51. Holvoet P., Mertens A., Verhamme P., et al. Circulating oxidized LDL is a useful marker for identifying patients with coronary artery disease. Arterioscler Thromb Vasc Biol 21 (2001) 844-848
52. Holvoet P., Collen D., and van de Werf F. Malondialdehyde-modified LDL as a marker of acute coronary syndromes. JAMA 281 (1999) 1718-1721
53. Ehara S., Ueda M., Naruko T., et al. Elevated levels of oxidized low density lipoprotein show a positive relationship with the severity of acute coronary syndromes. Circulation 103 (2001) 1955-1960
54. Nishi K., Itabe H., Uno M., et al. Oxidized LDL in carotid plaques and plasma associates with plaque instability. Arterioscler Thromb Vasc Biol 22 (2002) 1649-1654
55. Anselmi M., Garbin U., Agostoni P., et al. Plasma levels of oxidized-low-density lipoproteins are higher in patients with unstable angina and correlated with angiographic coronary complex plaques. Atherosclerosis 185 (2006) 114-120
56. Segev A., Strauss B.H., Witztum J.L., et al. Relationship of a comprehensive panel of plasma oxidized low-density lipoprotein markers to angiographic restenosis in patients undergoing percutaneous coronary intervention for stable angina. Am Heart J 150 (2005) 1007-1014
57. Braun S., Ndrepepa G., von Beckerath N., et al. Lack of association between circulating levels of plasma oxidized low-density lipoproteins and clinical outcome after coronary stenting. Am Heart J 150 (2005) 550-556
58. Naruko T., Ueda M., Ehara S., et al. Persistent high levels of plasma oxidized low-density lipoprotein after acute myocardial infarction predict stent restenosis. Arterioscler Thromb Vasc Biol 26 (2006) 877-883
59. Diepeveen S.H., Verhoeven G.W., Van Der P.J., et al. Effects of atorvastatin and vitamin E on lipoproteins and oxidative stress in dialysis patients: a randomised-controlled trial. J Intern Med 257 (2005) 438-445
60. Ndrepepa G., Braun S., von Beckerath N., et al. Oxidized low density lipoproteins, statin therapy and severity of coronary artery disease. Clin Chim Acta 360 (2005) 178-186
61. Shimada K., Mokuno H., Matsunaga E., et al. Circulating oxidized low-density lipoprotein is an independent predictor for cardiac event in patients with coronary artery disease. Atherosclerosis 174 (2004) 343-347
62. Meisinger C., Baumert J., Khuseyinova N., et al. Plasma oxidized low-density lipoprotein, a strong predictor for acute coronary heart disease events in apparently healthy, middle-aged men from the general population. Circulation 112 (2005) 651-657
63. Wallenfeldt K., Fagerberg B., and Wikstrand J. Oxidized low-density lipoprotein in plasma is a prognostic marker of subclinical atherosclerosis development in clinically healthy men. J Intern Med 256 (2004) 413-420
64. Binder C.J., Shaw P.X., Chang M.K., et al. The role of natural antibodies in atherogenesis. J Lipid Res 46 7 (2005) 1353-1363
65. Uno M., Harada M., Takimoto O., et al. Elevation of plasma oxidized LDL in acute stroke patients is associated with ischemic lesions depicted by DWI and predictive of infarct enlargement. Neurol Res 27 (2005) 94-102
66. Uno M., Kitazato K.T., Nishi K., et al. Raised plasma oxidised LDL in acute cerebral infarction. J Neurol Neurosurg Psychiatry 74 (2003) 312-316
67. Dei R., Takeda A., Niwa H., et al. Lipid peroxidation and advanced glycation end products in the brain in normal aging and in Alzheimer's disease. Acta Neuropathol (Berl) 104 (2002) 113-122
68. Holvoet P., Stassen J.M., Van Cleemput J., et al. Oxidized low density lipoproteins in patients with transplant-associated coronary artery disease. Arterioscler Thromb Vasc Biol 18 (1998) 100-107
69. Tsutsui T., Tsutamoto T., Wada A., et al. Plasma oxidized low-density lipoprotein as a prognostic predictor in patients with chronic congestive heart failure. J Am Coll Cardiol 39 (2002) 957-962
70. Svenungsson E., Jensen-Urstad K., Heimburger M., et al. Risk factors for cardiovascular disease in systemic lupus erythematosus. Circulation 104 (2001) 1887-1893
71. Pratico D., Rokach J., Lawson J., et al. F2-isoprostanes as indices of lipid peroxidation in inflammatory diseases. Chem Phys Lipids 128 (2004) 165-171
72. Morrow J.D. Quantification of isoprostanes as indices of oxidant stress and the risk of atherosclerosis in humans. Arterioscler Thromb Vasc Biol 25 (2005) 279-286
73. Morrow J.D., and Roberts L.J. Mass spectrometric quantification of F2-isoprostanes in biological fluids and tissues as measure of oxidant stress. Methods Enzymol 300 (1999) 3-12
74. Liang Y., Wei P., Duke R.W., et al. Quantification of 8-iso-prostaglandin-F(2alpha) and 2,3-dinor-8-iso-prostaglandin-F(2alpha) in human urine using liquid chromatography-tandem mass spectrometry. Free Radic Biol Med 34 (2003) 409-418
75. Bohnstedt K.C., Karlberg B., Wahlund L.O., et al. Determination of isoprostanes in urine samples from Alzheimer patients using porous graphitic carbon liquid chromatography-tandem mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci 796 (2003) 11-19
76. Pratico D. Lipid peroxidation in mouse models of atherosclerosis. Trends Cardiovasc Med 11 (2001) 112-116
77. Praticó D., Tangirala R.K., Rader D.J., et al. Vitamin E suppresses isoprostane generation in vivo and reduces atherosclerosis in ApoE-deficient mice. Nat Med 4 (1998) 1189-1192
78. Tangirala R.K., Pratico D., FitzGerald G.A., et al. Reduction of isoprostanes and regression of advanced atherosclerosis by apolipoprotein E. J Biol Chem 276 (2001) 261-266
79. Pratico D., Tangirala R.K., Horkko S., et al. Circulating autoantibodies to oxidized cardiolipin correlate with isoprostane F(2alpha)-VI levels and the extent of atherosclerosis in ApoE-deficient mice: modulation by vitamin E. Blood 97 (2001) 459-464
80. Davi G., Alessandrini P., Mezzetti A., et al. In vivo formation of 8-Epi-prostaglandin F2 alpha is increased in hypercholesterolemia. Arterioscler Thromb Vasc Biol 17 (1997) 3230-3235
81. Reilly M.P., Praticó D., Delanty N., et al. Increased formation of distinct F2 isoprostanes in hypercholesterolemia. Circulation 98 (1998) 2822-2828
82. De Caterina R., Cipollone F., Filardo F.P., et al. Low-density lipoprotein level reduction by the 3-hydroxy-3-methylglutaryl coenzyme-A inhibitor simvastatin is accompanied by a related reduction of F2-isoprostane formation in hypercholesterolemic subjects: no further effect of vitamin E. Circulation 106 (2002) 2543-2549
83. Davi G., Ciabattoni G., Consoli A., et al. In vivo formation of 8-iso-prostaglandin f2alpha and platelet activation in diabetes mellitus: effects of improved metabolic control and vitamin E supplementation. Circulation 99 (1999) 224-229
84. Gopaul N.K., Anggard E.E., Mallet A.I., et al. Plasma 8-epi-PGF2 alpha levels are elevated in individuals with non-insulin dependent diabetes mellitus. FEBS Lett 368 (1995) 225-229
85. Morrow J.D., Frei B., Longmire A.W., et al. Increase in circulating products of lipid peroxidation (F2-isoprostanes) in smokers. Smoking as a cause of oxidative damage. N Engl J Med 332 (1995) 1198-1203
86. Reilly M., Delanty N., Lawson J.A., et al. Modulation of oxidant stress in vivo in chronic cigarette smokers. Circulation 94 (1996) 19-25
87. Minuz P., Patrignani P., Gaino S., et al. Increased oxidative stress and platelet activation in patients with hypertension and renovascular disease. Circulation 106 (2002) 2800-2805
88. Davi G., Di Minno G., Coppola A., et al. Oxidative stress and platelet activation in homozygous homocystinuria. Circulation 104 (2001) 1124-1128
89. Voutilainen S., Morrow J.D., Roberts L.J., et al. Enhanced in vivo lipid peroxidation at elevated plasma total homocysteine levels. Arterioscler Thromb Vasc Biol 19 (1999) 1263-1266
90. Pratico D., Iuliano L., Mauriello A., et al. Localization of distinct F2-isoprostanes in human atherosclerotic lesions. J Clin Invest 100 (1997) 2028-2034
91. Gniwotta C., Morrow J.D., Roberts L.J., et al. Prostaglandin F2-like compounds, F2-isoprostanes, are present in increased amounts in human atherosclerotic lesions. Arterioscler Thromb Vasc Biol 17 (1997) 3236-3241
92. Mallat Z., Nakamura T., Ohan J., et al. The relationship of hydroxyeicosatetraenoic acids and F2-isoprostanes to plaque instability in human carotid atherosclerosis. J Clin Invest 103 (1999) 421-427
93. Cipollone F., Ciabattoni G., Patrignani P., et al. Oxidant stress and aspirin-insensitive thromboxane biosynthesis in severe unstable angina. Circulation 102 (2000) 1007-1013
94. Iuliano L., Pratico D., Greco C., et al. Angioplasty increases coronary sinus F2-isoprostane formation: evidence for in vivo oxidative stress during PTCA. J Am Coll Cardiol 37 (2001) 76-80
95. Reilly M.P., Delanty N., Roy L., et al. Increased formation of the isoprostanes IPF2{alpha}-I and 8-epi-prostaglandin F2{alpha} in acute coronary angioplasty: Evidence for oxidant stress during coronary reperfusion in humans. Circulation 96 (1997) 3314-3320
96. Delanty N., Reilly M.P., Praticó D., et al. 8-Epi PGF2{α} generation during coronary reperfusion: A potential quantitative marker of oxidant stress in vivo. Circulation 95 (1997) 2492-2499